Summary Squamous cell carcinomas of the anus are rare neoplasias that account for about 3% of large bowel tumours. Infections with human papillomaviruses are frequently detected in these cancers, suggesting that pathogenic pathways in anal carcinomas and in carcinomas of the uterine cervix are similar. Little is known regarding recurrent chromosomal aberrations in this subgroup of squamous cell carcinomas. We have applied comparative genomic hybridization to identify chromosomal gains and losses in 23 cases of anal carcinomas.
Comparative genomic hybridization (CGH) serves as a cytogenetic screening test that allows the mapping of chromosomal copy number changes in tumour genomes on normal metaphase chromosomes (Kallioniemi et al; . Only genomic tumour DNA is required for analysis. Consequently, CGH can be performed using DNA extracted from formalin-fixed and paraffin-embedded specimens (Speicher et al, 1993; Isola et al, 1994) . This feature allows the retrospective determination of chromosomal aberrations in archived tumour material . CGH is a well-suited tool to compare chromosomal aberrations with additional pertinent characteristics of specific tumours, such as histology, DNA ploidy and immunohistochemistry Ried et al, 1996) . We have recently established a phenotype-genotype correlation in the genesis of HPV-positive squamous cell carcinomas of the cervix uteri (Heselmeyer et al, , 1997 . We observed a characteristic pattern of genetic and phenotypic changes that were specific for cervical carcinogenesis: the gain of the long arm of chromosome 3 occurred in virtually all HPV-positive, aneuploid invasive carcinomas; and low expression of p53 was accompanied by high levels of p21/WAF-1. In order to understand whether the observed genotype-phenotype pattern represents a common pathogenic pathway in HPV-induced squamous cell carcinomas, we have extended the CGH analysis to squamous cell carcinomas of the anus. Anal squamous cell carcinomas are rare tumours for which natural history is incompletely understood (Williams et al, 1994) . It is clear, however, that HPV genomes are frequently detected in these tumours and their precursor lesions (Zaki et al, 1992; Heino et al, 1993; Palefsky, 1994) and that cervical and anal cancers have similar risk factors and pathology (IARC monograph, 1995) . Only a few reports on the cytogenetics of anal carcinomas are available. Muleris et al (1987) identified the recurrent loss of chromosome arms 3p and 1 lq in a series of eight tumours (Muleris et al, 1987) . We used CGH to screen 23 carcinomas of the anus for chromosomal copy number changes. The same tumour section that was used for CGH was analysed for the presence of HPV genomes. Adjacent serial sections were examined for crude DNA ploidy by image cytometry, for proliferative activity (MIB-1), for the expression level of the tumour-suppressor gene TP53 and the cyclin-dependent kinase inhibitor p21/WAFl.
MATERIALS AND METHODS Tissue microdissection and DNA extraction
Tumour material was collected at hospitals throughout Sweden between 1985 and 1989 and diagnosed on haematoxylin and eosin-stained tissue sections. The clinical data are summarized in Table 1 . Consecutive sections were prepared from each sample and used for histological diagnosis (4,m thick), DNA ploidy measurement (8 ,um), immunohistochemistry (4 jim) and genomic DNA extraction (50 jm). A second 4-jm section was stained to confirm the presence of tumour tissue. All analyses were performed on these samples. (Auer et al, 1989; Steinbeck et al, 1995 Immunohistochemistry was performed essentially as described . Examples of the immunohistochemical staining are presented in Figure 2 .
HPV genotyping HPV genomes in the purified specimen DNA were identified by polymerase chain reaction (PCR) using the MY09-MY 11 LI consensus primers for amplification (Bosch et al, 1995) . Twentyfive type-specific probes and a generic HPV probe were used to diagnose the HPV type in the PCR products as described in detail elsewhere (Hildesheim et al, 1994 Labelling was performed by nick translation substituting dTTP by biotin-16-dUTP (Boehringer Mannheim). Of each differentially labelled genome, 500 ng was precipitated together with an excess (30 jg) of the Cot-I fraction of human DNA (Gibco BRL). The probe DNA was resuspended in 10 g1 of hybridization solution (50% formamide, 2 x standard saline citrate (SSC), 10% dextran sulphate), denatured (5 min, 75°C) and preannealed for 1 h at 37°C. The normal metaphase chromosomes were denatured separately (70% formamide, 2 x SSC) for 2 min at 75°C and dehydrated through an ethanol series. Hybridization took place under a coverslip for 2-4 days at 37°C. Post-hybridization washes and immunocytochemical detection was performed as described . Biotin-labelled tumour sequences were detected with avidin conjugated to FITC (Vector laboratories), and the digoxigenin-labelled reference DNA was developed using a mouse anti-digoxigenin antibody, followed by a TRITC-conjugated anti-mouse antibody (Sigma Chemicals) . The slides were British Joumal of Cancer (1997) 76 (10), [1271] [1272] [1273] [1274] [1275] [1276] [1277] [1278] . 
Microscopy and image analysis
Grey-level images were acquired for each fluorochrome with a cooled CCD camera (Photometrics, Tucson, AZ, USA) coupled to a Leica DMRBE epifluorescence microscope using sequential exposure through fluorochrome specific filters (TRI, TR2, TR3, Chroma Technology). Chromosomes were identified using DAPIbanding. Fluorescence ratio images were calculated by a custom computer program (du and run on a Macintosh Quadra 950 ( Figure 2D and F) . Average ratio profiles were calculated from at least eight ratio images. After the determination of the chromosomal axis for each chromosome in every metaphase, individual FITC and TRITC profiles were calculated. These were used for the computation of the ratio (FITC/TRITC) profiles. The three vertical lines on the right side of the chromosome ideogram represent different values of the fluorescence ratios between the tumour and the normal DNA (Figure 3) . The values are 0.75, 1 and 1.25 from left to right. These values were chosen as thresholds for the identification of DNA copy number decreases (below 0.75) and increases (above 1.25) as described in du . The curve shows the ratio profiles that were computed as mean values of at least eight metaphase spreads. Average ratio profiles were the basis for all evaluations.
RESULTS
CGH was used to identify chromosomal copy number changes in a series of 23 anal squamous cell carcinomas. The clinical data are presented in Table 1 . The molecular cytogenetic analysis was complemented by HPV genotyping and DNA ploidy measurements. The proliferative activity and the expression levels of the tumour-suppressor gene p53 and the cyclin-dependent kinase inhibitor p21/WAF-1 were analysed on the same tissue sections. The combined data allow for a phenotype/genotype correlation in this rare subgroup of squamous cell carcinomas. Table 2 summarizes the data.
CGH
The CGH analysis revealed a recurrent pattem of chromosomal gains and losses. Figure 2D and F presents ratio images from tumours 5 and 8. An average ratio profile for case 8 is presented in Figure 3 . The average ratio profile was used for the identification of copy number changes in all cases. The karyogram of chromosomal gains and losses is summarized in Figure 4 . Chromosomal gains were mapped to chromosome 19 (14 of 23 cases), chromosome 17 (9 of 23 cases), chromosome 3q (7 of 23 cases) and chromosome 22 (5 of 23 cases). Consistent losses occurred on chromosomes 11 (9 of 23 cases), 18 (8 of 23 cases), 4p (7 of 23 cases) and 13 (6 of 23 cases). High-level copy number increases were observed infrequently on chromosome 3q (two cases) and on chromosome band 2p23-24. All tumours showed chromosomal copy number alterations. In 23 tumours, 110 copy number changes were observed, resulting in an average number of copy alterations (ANCA) of 4.8. In 90 of 110 copy number changes (82%), entire chromosomes or chromosome arms were subject to gain or loss.
British Journal of Cancer (1997) 7t~~~S . HPV genotyping HPV genotyping was performed on the genomic tumour DNA that was used for CGH as described. Seven tumour DNAs in which Pglobin could not be amplified were scored as unsatisfactory. In the remaining sixteen tumours, HPV 16 was detected in eight tumours; in one tumour, the HPV type could not be identified. Seven tumours were negative for HPV. Aneuploid DNA histograms were seen in six of seven HPV-positive and four of seven HPV-negative tumours. The data are summarized in Table 2 .
DNA ploidy
The majority of the cases studied by image cytometry on consecutive sections revealed an aneuploid DNA histogram with a main peak in the tetraploid region (4c) and more than 20% of the cells exceeding Sc. Only two of the anal carcinomas remained diploid. One of the diploid tumours revealed, as a sole anomaly, the loss of one X chromosome. However, the second diploid tumour showed multiple chromosomal aberrations. Three tumours revealed a clear tetraploidization with peak values between 3.9c and 4. Ic. There was no obvious correlation between the number of copy alterations and the ploidy. Examples of the histograms are presented in Figure  1 and a summary of the ploidy measurements is given in Figure 2 presents examples of the immunohistochemistry of case 8, which exemplifies the consistent staining pattern, and of case 5, which revealed an exceptional immunostaining. A summary of the quantification is provided in Table 2 .
DISCUSSION
We conducted a molecular cytogenetic study of 23 cases of anal squamous cell carcinomas by CGH. The cytogenetic data were complemented by DNA ploidy measurements, HPV genotyping and expression level analysis of the proliferation marker Ki-67, the tumour-suppressor gene product p53 and the cyclin-dependent kinase inhibitor p21/WAF-l. CGH analysis revealed a recurrent pattern of chromosomal gains and losses. Chromosomes 11, 18, 13 and 4p were most frequently under-represented, whereas copy number gains were consistently mapped to chromosomes 19, 17 and 3q. It should be noted that copy number changes involving chromosome 19 require cautious interpretation if they occur simultaneously with changes on chromosomes lp, 16 and 22. These chromosomal regions are known to be rich in Alu-repeat sequences, which may cause unspecific ratio variations. However, chromosome 19 was independently subjected to copy number increases. In three instances, high-level copy number increases (amplifications) were identified on chromosome arm 3q and or chromosomal bands 3q26-28 and 2p23-24. The amplification on 2p24 coincides with the chromosomal mapping position of the N-myc proto-oncogene.
Reports on chromosomal aberrations by means of chromosome banding analyses are rare. Muleris et al (1987) reported the nonrandom loss of chromosomes 3p and 1 lq. While chromosome 3p is affected in only 2 of 23 cases in our study, the loss of chromosome 1 lq occurs in 9 of 23 of our cases. The minimally deleted region encompasses chromosome bands 1 Iq14-25. The recurrent loss of this chromosomal region suggests that this region harbours a tumour-suppressor gene involved in the genesis of anal squamous cell carcinomas. The average number of copy alterations (ANCA) amounts to 4.8 per tumour. In a previously performed series of stage TI cervical carcinomas, the ANCA per tumour was 4.0 . No correlation between the ANCA per tumour and the ploidy, the presence of HPV infection or the differentiation and tumour stage was obvious in anal squamous cell carcinomas. The immunohistochemical analysis of the same samples that were used for CGH revealed a consistent pattern: in the . It is not clear whether the strong expression of p21/WAF-l indicates that the inactivation of p53 via the E6 protein of HPV is incomplete (Butz et al, 1995) or whether p21/WAF-l expression is up-regulated using alternate regulatory pathways (Parker et al, 1995; Chin et al, 1996) . p53 expression levels show no correlation with HPV infection.
We have previously established a phenotype-genotype correlation in cervical and colon carcinogenesis Ried et al, 1996) . When 
